The transaction includes BioReference Health's proprietary 4Kscore test, an FDA-approved blood test used to evaluate the likelihood of aggressive prostate cancer prior to a biopsy.

Cancer treatment, oncology drug access, hematologic malignancies, and cancer drug policy.

Bryan Johnson, rapamycin, NAD+, cellular reprogramming, biological age tests, peptides, and emerging longevity interventions.

Specific solid tumor cancer types organized by organ system and tissue origin.

Cancer prevention strategies, screening, early detection, and diagnostic approaches.